Effect of Safinamide on Sleep Quality in Patients With Parkinson's Disease

A Prospective, Open Label, Single Arm, Clinical Study to Evaluate the Effect of Safinamide on Sleep Quality and Polysomnographic Parameters in Patients With Parkinson's Disease: the Safe Sleep Study

Patients suffering of Parkinson's Disease will be treated with 50 mg/day of Safinamide per os for 2 weeks (escalation phase). Then, safinamide will be increased up to 100 mg/day and, if tolerated, the treatment will be taken for 10 more weeks (maintenance phase). Total treatment 12 weeks.

Study Overview

• Status: Recruiting
• Conditions: Idiopathic Parkinson's Disease (at Later Stage)
• Intervention / Treatment: Drug: Safinamide

Detailed Description

Adult patients affected by PD and suffering from motor fluctuations will be screened for participation.

If the inclusion and exclusion criteria are met, the participant will enter in the baseline assessment phase and undergo 1 night baseline PSG and 1 week baseline actigraphy. The patient will then start the treatment with 50 mg/day of Safinamide per os for 2 weeks (escalation phase). Then, safinamide will be increased up to 100 mg/day and, if tolerated, the treatment will last for 10 weeks (maintenance phase). At week 12 (end of treatment), the questionnaires, actigraphy and PSG will be repeated. A safety follow-up visit is scheduled 4 weeks after study treatment completion.

The treatment will be continued thereafter in all patients if medically indicated.

• Study Type: Interventional
• Enrollment (Estimated): 23
• Phase: Phase 4

Contacts and Locations

• Study Contact: Name: Alain Kaelin, Prof; Phone Number: +41 (0)91 811 62 57; Email: alain.kaelin@eoc.ch
• Study Contact Backup: Name: Ilaria Bertaina, MD; Phone Number: +41 (0)91 811 63 74; Email: ilaria.bertaina@eoc.ch

Study Locations

• Switzerland
  • Lugano, Switzerland, 6900
    • Recruiting
    • Neurocenter of Southern Switzerland - Ente Ospedaliero Cantonale (EOC)
    • Contact: Alain Kaelin, Prof.; Phone Number: +41 (0)91 811 62 57; Email: alain.kaelin@eoc.ch
    • Contact: Ilaria Bertaina, MD; Phone Number: +41 (0)91 811 69 15 -; Email: ilaria.bertaina@eoc.ch
    • Sub-Investigator: Mauro Manconi, Prof.
    • Sub-Investigator: Ilaria Bertaina, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Age ≥ 18 years old
• Fluctuating idiopathic PD patients according to UK Brain bank Criteria
• Hoehn and Year II to IV under treatment
• Sleep disturbance with a Pittsburgh Sleep Quality Index (PSQI) > 5
• Treatment with L-DOPA, alone or with other dopaminergic drugs, at a stable dose since at least 28 days prior to inclusion
• Treatment with all substances potentially acting on sleep and mood must be constant since at least 28 days prior to inclusion
• Written informed consent
• Willingness and ability to participate in the trial

Exclusion Criteria:

• Off label use of safinamide
• Early PD or absence of PD fluctuations
• Concomitant treatment with other MAO-B inhibitors (wash-out period: at least 14 days)
• Atypical Parkinsonism
• Severe known sleep-related breathing disorders with any specific treatment or severe known sleep-related breathing disorders (apnoea-hypopnea index score >30/h) with or without a specific treatment
• Dementia (MoCA < 26)
• Severe depression (BDI-II ≥ 29)
• Other severe psychiatric symptoms such as active psychosis or major hallucinations
• Any previous or concomitant severe medical conditions or clinical laboratory abnormality which, in the clinical judgement of the Investigators, does not allow patients' participation into the study
• Moderate or severe hepatic impairment, any type of retinopathy and/or any pathology that is deemed to be a contraindication according to safinamide's SmPC
• Any concomitant treatment not allowed or contraindicated in the safinamide SmPC
• Women who are pregnant or breast feeding
• Lack of safe contraception, defined as: Female participants of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Safinamide; PO treatment: 2 weeks of treatment at dose 50 mg/day followed by 10 weeks at 100 mg/day	Drug: Safinamide; Safinamide taken per Os for 12 weeks; Other Names: Xadago

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Effect of safinamide on overall sleep quality	To measure the change in PDSS-2 (Parkinson's Disease Sleep Scale Version 2) score and the changes in sleep maintenance (=total sleep time/partial sleep time) and sleep efficiency (=total sleep time/ time in bed) scores measured by polysomnography (PSG). PDSS-2 total score ranges from 0 (no disturbance) to 60 (maximum nocturnal disturbance). Scores > 18 are considered as relevant sleep disturbances.	12 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Effect of safinamide on objective PSG sleep characterization	To determine neurophysiological sleep parameters from PSG recording	12 weeks
Effect of safinamide on subjective sleep quality and sleepiness	To measure the change in subjective sleep quality as measured by PDSS-2 subscores and by the electronic diary "Sleep Fit app", and in daytime sleepiness as measured by ESS (Epworth sleepiness scale) score. PDSS-2 total score ranges from 0 (no disturbance) to 60 (maximum nocturnal disturbance). Scores > 18 are considered as relevant sleep disturbances. ESS score ranges from 0 to 24. Scores > 10 suggest relevant daytime sleepiness.	12 weeks
Effect of safinamide on objective motor activity	To determine the change in motor activity as measured by a specific objective measure of bradykinesia (FitTest) in the electronic diary "Sleep Fit app".	12 weeks
Effect of safinamide on subjective motor activity	To measure the change in motor activity as measured by UPDRS (Unified Parkinson's Disease Rating Scale). Higher UPDRS score indicates more severe impairment of non-motor and motor activities.	12 weeks
Effect of safinamide on objective sleep parameters and motor symptoms	To measure the change in sleep parameters and motor activity during the day and the night as measured by actigraphy.	12 weeks
Effect of safinamide on non-motor symptoms	To measure the change in depressive symptoms as measured by (BDI-II) Beck Depression Inventory and SAS (Starkstein Apathy Scale). Total BDI-II score ranges from 0 to 63 with higher total score indicating more severe depressive symptoms. Total SAS score ranges from 0 to 42 with higher scores indicating more severe apathy.	12 weeks
Effect of safinamide on quality of life	To measure the change in quality of life as measured by PDQ-39 (Parkinson's Disease Questionnaire-39). PDQ-39 is scored on a scale of 0 to 100, with lower scores indicating better health and high scores more severe symptoms.	12 weeks

Collaborators and Investigators

• Sponsor: Alain Kaelin
• Collaborators: Clinical Trial Unit Ente Ospedaliero Cantonale

Study record dates

Study Major Dates

• Study Start (Actual): February 18, 2019
• Primary Completion (Estimated): April 30, 2025
• Study Completion (Estimated): April 30, 2025

Study Registration Dates

• First Submitted: April 19, 2019
• First Submitted That Met QC Criteria: May 29, 2019
• First Posted (Actual): May 30, 2019

Study Record Updates

• Last Update Posted (Actual): March 15, 2024
• Last Update Submitted That Met QC Criteria: March 14, 2024
• Last Verified: March 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Parkinsonian Disorders; Basal Ganglia Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases; Parkinson Disease
• Other Study ID Numbers: NSI-SAF-001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No